生物活性 | |||
---|---|---|---|
描述 | 3BDO is a new mTOR activator which can also inhibit autophagy. It inhibited autophagy in human umbilical vein endothelial cells (HUVECs) and neuronal cells. 3BDO activated MTOR by targeting FKBP1A (FK506-binding protein 1A, 12 kDa). Activation of mTOR by 3BDO increased the phosphorylation of TIA1 (TIA1 cytotoxic granule-associated RNA binding protein/T-cell-restricted intracellular antigen-1)[1]. In vivo experiments confirmed that 3BDO activated mTOR and decreased the protein level of ATG13 in the plaque endothelium of apoE(-/-) mice. Importantly, 3BDO did not affect the activity of mTOR and autophagy in macrophage cell line RAW246.7 and vascular smooth muscle cells of apoE(-/-) mice, but suppressed plaque endothelial cell death and restricted atherosclerosis development in the mice. 3BDO protected VECs by activating mTOR and thus stabilized atherosclerotic lesions in apoE(-/-) mice[2]. 3BDO increased levels of insulin-degrading enzyme and neprilysin, suppressed autophagy via an mTOR pathway, lowered levels of Aβ, and prevented AD-like cognitive deficits in the AβPP/PS1 double transgenic mouse model[3]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.06mL 0.61mL 0.31mL |
15.28mL 3.06mL 1.53mL |
30.55mL 6.11mL 3.06mL |
参考文献 |
---|